Adverse Reactions to Biologic Therapy

Sheenal V. Patel, David A. Khan

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients.

Original languageEnglish (US)
Pages (from-to)397-412
Number of pages16
JournalImmunology and Allergy Clinics of North America
Volume37
Issue number2
DOIs
StatePublished - May 1 2017

Keywords

  • Biologic agents
  • Delayed reaction
  • Drug desensitization
  • Infusion reaction
  • Monoclonal antibodies
  • Omalizumab
  • Rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Adverse Reactions to Biologic Therapy'. Together they form a unique fingerprint.

  • Cite this